Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

BACKGROUND: The anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion and 3.5-4 hours thereafter, thus making dar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonello, Francesca, Rocchi, Serena, Barilà, Gregorio, Sandrone, Michela, Talarico, Marco, Zamagni, Elena, Scaldaferri, Matilde, Vedovato, Susanna, Bertiond, Cecilia, Pavan, Laura, Bringhen, Sara, Cattel, Francesco, Zambello, Renato, Cavo, Michele, Mina, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964091/
https://www.ncbi.nlm.nih.gov/pubmed/35359355
http://dx.doi.org/10.3389/fonc.2022.851864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964091/
https://www.ncbi.nlm.nih.gov/pubmed/35359355
http://dx.doi.org/10.3389/fonc.2022.851864

Ejemplares similares